Clinical Trial

Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-19; most recent amendment 2025-03-03.
Status change: Not Yet Recruiting → Recruiting 2025-02-17
Trial Details
NCT Number NCT06565247
Lead Sponsor Region Västerbotten
Collaborators: Umeå University, Region Skane, Lund University
Conditions Prostate Cancer
Enrollment 60 participants
Start Date 2024-10-14
Primary Completion 2026-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-04